Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer

(2011) K. Aogi et al.   ANNALS OF ONCOLOGY

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

(2011) Javier Cortes et al.   LANCET

Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine

(2010) Javier Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Eribulin Binds at Microtubule Ends to a Single Site on Tubulin To Suppress Dynamic Instability

(2009) Jennifer A. Smith et al.   BIOCHEMISTRY

Breast Cancer Subtypes as Defined by the Estrogen Receptor (ER), Progesterone Receptor (PR), and the Human Epidermal Growth Factor Receptor 2 (HER2) among Women with Invasive Breast Cancer in California, 1999-2004

(2009) Carol A. Parise et al.   Breast Journal

Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2009) Linda T. Vahdat et al.   JOURNAL OF CLINICAL ONCOLOGY

Taxanes Alone or in Combination With Anthracyclines As First-Line Therapy of Patients With Metastatic Breast Cancer

(2008) Martine J. Piccart-Gebhart et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase

(2008) T. Okouneva et al.   MOLECULAR CANCER THERAPEUTICS